Idiopathic pulmonary fibrosis: possibilities of multidisciplinary diagnostic approach
https://doi.org/10.18093/0869-0189-2018-28-5-622-625
Abstract
Idiopathic pulmonary fibrosis (IPF) is the commonest form of idiopathic interstitial pneumonias with very poor prognosis. Currently, diagnostic and treatment approaches to this disease have been revised. Confirmation of the diagnosis requires careful exclusion of other known causes of interstitial lung diseases and the presence of usual interstitial pneumonia (UIP) pattern on high-resolution computed tomography (HRTC) and/or on lung biopsy. Also, multidisciplinary discussion involving experts with experience in the diagnosis of interstitial lung diseases is recommended. Given recent knowledge on pathogenesis of IPF antifibrotic drugs are recommended for the therapy of this disease. A clinical case that demonstrates the multidisciplinary approach to diagnosis of IPF is reported in this article.
About the Authors
A. М. Kardangusheva
State Federal-Funded Educational Institution of Higher Professional Training Kabardino-Balkarian State University named after Kh.M.Berbekov
Russian Federation
Russian Federation
Aksana M. Kardangusheva – Doctor of Medicine., Professor, Chair of Propaedeutics of Internal Diseases
ul. Chernyshevskogo 173, Nalchik, 360004
Н. A. Sabanchieva
State Federal-Funded Educational Institution of Higher Professional Training Kabardino-Balkarian State University named after Kh.M.Berbekov
Russian Federation
Russian Federation
Haishat A. Sabanchieva – Candidate of Medicine, Assistant Professor, Chair of Propaedeutics of Internal Diseases
ul. Chernyshevskogo 173, Nalchik, 360004
References
1. Raghu G., Rochwerg B., Zhang Y. et al. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline. Am. J. Respir. Crit. Care Med. 2015; 192 (2): e3–e19. DOI: 10.1164/rccm.201506-1063ST.
2. Chuchalin A.G., Avdeev S.N., AisanovZ.R.etal. Diagnosis and Treatment of Idiopathic Pulmonary Fibrosis. Federal Guidelines.Pul'monologiya. 2016; 26 (4): 399–419. DOI: 10.18093/0869-0189-2016-26-4-399-419.
3. Raghu G., Chen S.Y., Yeh W.S. et al. Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older: incidence, prevalence, and survival, 2001–11. Lancet Respir. Med. 2014; 2 (7): 566–572. DOI: 10.1016/S2213-2600(14)70101-8.
4. Wolters P.J., Collard H.R., Jones K.D. Pathogenesis of idiopathic pulmonary fibrosis. Annu. Rev. Pathol. 2014; (9): 157–179. DOI: 10.1146/annurev-pathol-012513-104706.
5. Richeldi L., Rubin A.S., Avdeev S. et al. Idiopathic pulmonary fibrosis in BRIC countries: the cases of Brasil, Russia, India and China. BMC Med. 2015; (13): 237. DOI: 10.1186/s12916-015-0495-0.
6. Soo E., Adamali H., Edey A.J. Idiopathic pulmonary fibrosis: current and future directions. Clin. Radiol. 2017; 72 (5): 343–355. DOI: 10.1016/j.crad.2016.12.014.
7. RoglianiР., Calzetta L., Cavalli F. et al. Pirfenidone, nintedanib and N-acetylcysteine for the treatment of idiopathic pulmonary fibrosis: a systematic review and meta-analysis. Pulm. Pharmacol. Ther. 2016; 40: 95-103. DOI: 10.1016/j.pupt.2016.07.009.
8. Coward W.R., Saini G., Jenkins G. The pathogenesis of idiopathic pulmonary fibrosis. Ther. Adv. Respir. Dis. 2010; 4 (6): 367–388. DOI: 10.1177/1753465810379801.
9. Wollin L., Maillet I., Quesniaux V. et al. Anti-fibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis. J. Pharmacol. Exp. Ther. 2014; 349 (2): 209–220. DOI: 10.1124/jpet.113.208223.
10. Richeldi L., Cottin V., du Bois R.M. et al. Nintedanib in patients with idiopathic pulmonary fibrosis: Combined evidence from the TOMORROW and INPULSIS® trials. Respir. Med. 2016; (113): 74–79. DOI: 10.1016/j.rmed.2016.02.001.
11. Collard H.R., Richeldi L., Kim D.S. et al. Acute exacerbations in the INPULSIS trials of nintedanib in idiopathic pulmonary fibrosis. Eur. Respir. J. 2017; 49 (5): pii: 1601339. DOI: 10.1183/13993003.01339-2016.
12. Crestani B., Quaresma M., Kaye M. et al. Long-term treatment with nintedanib in patients with IPF: an update from INPULSIS®-ON. Eur. Respir. J. 2016; 48 (Suppl. 60): OA4960. DOI: 10.1183/13993003.congress-2016.OA4960.
13.
14.
15.
Review
For citations:
Kardangusheva A.М., Sabanchieva Н.A. Idiopathic pulmonary fibrosis: possibilities of multidisciplinary diagnostic approach. PULMONOLOGIYA. 2018;28(5):622-625. (In Russ.) https://doi.org/10.18093/0869-0189-2018-28-5-622-625
Views:
1007
Email this article 